Arabic Arabic English English French French German German
dark

Batavia Biosciences successfully manufactures IAVI’s Lassa fever vaccine candidate on innovative HIP-Vax platform to support Phase I clinical trials

Batavia Biosciences announces today that they have successfully produced vaccine material for a Phase I clinical trial of IAVI’s Lassa fever vaccine candidate, rVSV∆G-LASV-GPC. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease

Next Post

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events

Related Posts
Total
0
Share